Modulating the Cav-1/autophagy axis (e.g. inhibiting Cav-1 to enhance radiotherapy sensitivity in NSCLC, or overexpressing Cav-1 to inhibit autophagy and reverse paclitaxel resistance in osteosarcoma) may represent novel strategies to overcome therapeutic resistance in tumors. Here, CAV1 is linked to osteosarcoma.